Cargando…
Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Blackwell Publishing Ltd
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666085/ https://www.ncbi.nlm.nih.gov/pubmed/23464790 http://dx.doi.org/10.1111/papr.12040 |
| _version_ | 1782271347207962624 |
|---|---|
| author | Pergolizzi, Joseph V Gharibo, Christopher G Gudin, Jeffrey A Nalamachu, Srinivas R |
| author_facet | Pergolizzi, Joseph V Gharibo, Christopher G Gudin, Jeffrey A Nalamachu, Srinivas R |
| author_sort | Pergolizzi, Joseph V |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3666085 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Blackwell Publishing Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-36660852013-06-03 Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products Pergolizzi, Joseph V Gharibo, Christopher G Gudin, Jeffrey A Nalamachu, Srinivas R Pain Pract Editorial Blackwell Publishing Ltd 2013-04 2013-03-06 /pmc/articles/PMC3666085/ /pubmed/23464790 http://dx.doi.org/10.1111/papr.12040 Text en Copyright © 2013 World Institute of Pain http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
| spellingShingle | Editorial Pergolizzi, Joseph V Gharibo, Christopher G Gudin, Jeffrey A Nalamachu, Srinivas R Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products |
| title | Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products |
| title_full | Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products |
| title_fullStr | Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products |
| title_full_unstemmed | Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products |
| title_short | Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products |
| title_sort | development of federally mandated risk evaluation and mitigation strategies (rems) for transmucosal immediate-release fentanyl products |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666085/ https://www.ncbi.nlm.nih.gov/pubmed/23464790 http://dx.doi.org/10.1111/papr.12040 |
| work_keys_str_mv | AT pergolizzijosephv developmentoffederallymandatedriskevaluationandmitigationstrategiesremsfortransmucosalimmediatereleasefentanylproducts AT gharibochristopherg developmentoffederallymandatedriskevaluationandmitigationstrategiesremsfortransmucosalimmediatereleasefentanylproducts AT gudinjeffreya developmentoffederallymandatedriskevaluationandmitigationstrategiesremsfortransmucosalimmediatereleasefentanylproducts AT nalamachusrinivasr developmentoffederallymandatedriskevaluationandmitigationstrategiesremsfortransmucosalimmediatereleasefentanylproducts |